small molecule

IMBRUVICA

IBRUTINIB

Loss of exclusivitySeptember 2036latest FDA-listed patent expiry
CompanyPharmacyclicsSee this company's full patent-cliff portfolio

Drug detail

Brand nameIMBRUVICA
Active ingredientIBRUTINIB
Strength560MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2018
Marketing statusDISCN

Listed patents

PatentExpiresType
9655857*PEDSeptember 2036
10828259*PEDSeptember 2036
10010507*PEDSeptember 2036
10213386*PEDSeptember 2036
10010507March 2036product
10213386March 2036product
9655857March 2036product
10828259March 2036product
10695350*PEDApril 2035
9795604*PEDApril 2035
10463668*PEDApril 2035
10695350October 2034use U-2846
10463668October 2034use U-2654
9795604October 2034use U-2970
9296753*PEDApril 2034
10125140*PEDDecember 2033
9725455*PEDDecember 2033
10961251*PEDDecember 2033
10106548*PEDDecember 2033
9296753October 2033substance
9725455June 2033substance
10125140June 2033substance, product
10106548June 2033substance, product
10961251June 2033product
10478439*PEDDecember 2031
8999999*PEDDecember 2031
10751342*PEDDecember 2031
9801881*PEDDecember 2031
10653696*PEDDecember 2031
10004746*PEDDecember 2031
9125889*PEDDecember 2031
9814721*PEDDecember 2031
8754090*PEDDecember 2031
10016435*PEDDecember 2031
9801883*PEDDecember 2031
9125889June 2031use U-1650
9801881June 2031use U-2242
8999999June 2031use U-2242
10004746June 2031use U-2242
10016435June 2031use U-1650
8754090June 2031use U-1456
9814721June 2031use U-1947
10478439June 2031use U-1684
9801883June 2031use U-2159
10653696June 2031use U-1456
10751342June 2031use U-1491
8008309*PEDMay 2028
8008309November 2027substance, product
8563563*PEDOctober 2027
8497277*PEDJune 2027
8754091*PEDJune 2027
9181257*PEDJune 2027
8703780*PEDJune 2027
8957079*PEDJune 2027
8476284*PEDJune 2027
8735403*PEDJune 2027
7514444*PEDJune 2027
8952015*PEDJune 2027
8697711*PEDJune 2027
8563563April 2027use U-2242
8952015December 2026use U-2241
8697711December 2026substance, product
8957079December 2026substance, product
8735403December 2026substance, product
7514444December 2026substance, product
9181257December 2026substance
8754091December 2026product
8476284December 2026use U-2241
8497277December 2026use U-1456
8703780December 2026use U-2242

Regulatory exclusivity

CodeExpires
PEDFebruary 2030
ODE-405August 2029
PEDFebruary 2026
NPPAugust 2025

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

IMBRUVICA patent cliff — loss of exclusivity September 2036 | CliffBio